Yolanda Gonzalez
Overview
Explore the profile of Yolanda Gonzalez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
1429
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moreno D, Oriol A, Rubia J, Hernandez M, Inigo M, Palomera L, et al.
Clin Lymphoma Myeloma Leuk
. 2025 Feb;
PMID: 39955256
Purpose: Recent studies describe inferior outcomes in newly diagnosed multiple myeloma (NDMM) patients with t(11;14) treated with novel agents. Materials And Methods: We analyzed 240 NDMM transplant eligible (TE) patients...
2.
Garcia-Guinon A, Charry P, Jimenez M, Sarra J, Delgado I, Segura de la Torre L, et al.
Ann Hematol
. 2025 Feb;
PMID: 39954075
Carfilzomib, lenalidomide and dexamethasone (KRd) is still a widely used treatment option for patients with relapsed / refractory multiple myeloma (RRMM). However, there is limited real-world evidence. Here we evaluated...
3.
Sarkar S, Carranza C, Gonzalez Y, Zhang J, Osornio Vargas A, Ohman-Strickland P, et al.
Am J Respir Cell Mol Biol
. 2025 Jan;
72(2):222-225.
PMID: 39887972
No abstract available.
4.
Sarto J, Esteller-Gauxax D, Guillen N, Falgas N, Borrego-Ecija S, Massons M, et al.
J Neurol
. 2025 Jan;
272(2):160.
PMID: 39849125
Plasma tau phosphorylated at threonine 181 (p-tau181) and 217 (p-tau217) have demonstrated high accuracy for Alzheimer's disease (AD) diagnosis, defined by CSF/PET amyloid beta (Aβ) positivity, but most studies have...
5.
Salgado-Cantu M, Gutierrez-Gonzalez L, Guzman-Beltran S, Herrera M, Sarabia C, Gonzalez Y
Microorganisms
. 2025 Jan;
12(12.
PMID: 39770608
Tuberculosis (TB) is one of the most common respiratory infections worldwide, and it is caused by (). employs immune evasion mechanisms that allow the disease to become chronic. Despite extensive...
6.
Juarez E, Vazquez-Perez J, Carreto-Binaghi L, Martinez-Sanabria C, Salgado-Cantu M, Sarabia C, et al.
J Leukoc Biol
. 2024 Sep;
117(2).
PMID: 39327799
Viral RNA and miRNAs released by immune cells contribute to inflammation in COVID-19 patients. Here, we investigated the role of SARS-CoV2 RNA and host miRNAs carried within extracellular vesicles (EVs)...
7.
Alegre A, Gironella M, Escalante F, Bergua J, Martinez-Chamorro C, Lopez A, et al.
Hemasphere
. 2024 Jul;
8(7):e81.
PMID: 38974896
Recommendations regarding the best time to start treatment in patients with relapsed/refractory multiple myeloma (RRMM) after biological relapse/progression (BR) are unclear. This observational, prospective, multicenter registry aimed to evaluate the...
8.
Guzman-Beltran S, Juarez E, Cruz-Munoz B, Paez-Cisneros C, Sarabia C, Gonzalez Y
Biomolecules
. 2024 Apr;
14(4).
PMID: 38672491
Bactericidal permeability-increasing protein (BPI) is a multifunctional cationic protein produced by neutrophils, eosinophils, fibroblasts, and macrophages with antibacterial anti-inflammatory properties. In the context of Gram-negative infection, BPI kills bacteria, neutralizes...
9.
Gonzalez-Calle V, Rodriguez-Otero P, Sureda A, de Arriba F, Reinoso M, Ribas P, et al.
Haematologica
. 2024 Feb;
109(7):2219-2228.
PMID: 38356463
The treatment landscape for multiple myeloma has significantly evolved in the last decade. Notwithstanding, a large proportion of patients continue to relapse and novel combinations continue to be needed. In...
10.
Carranza C, Sartillo-Mendoza L, Carreto-Binaghi L, Munoz-Torrico M, Guzman-Beltran S, Torres M, et al.
Tuberculosis (Edinb)
. 2023 Oct;
143:102418.
PMID: 37813014
Pulmonary tuberculosis (TB) inflammation is an underestimated disease complication which anti-inflammatory drugs may alleviate. This study explored the potential use of the COX-2 inhibitors acetylsalicylic acid (ASA) and celecoxib in...